Stockscreener 앱 받기
44.72
1.22%
0.54
시간 외 거래:
44.72
전일 마감가:
$44.18
열려 있는:
$43.67
하루 거래량:
1.04M
Relative Volume:
0.75
시가총액:
$4.86B
수익:
-
순이익/손실:
$-176.01M
주가수익비율:
-26.92
EPS:
-1.661
순현금흐름:
$-148.97M
1주 성능:
+1.54%
1개월 성능:
+9.50%
6개월 성능:
+44.68%
1년 성능:
+201.14%
1일 변동 폭
$42.59
$45.44
1주일 범위
$42.59
$46.59
52주 변동 폭
$13.69
$48.40
엣지와이즈 Stock (EWTX) Company Profile
명칭
Edgewise Therapeutics Inc
전화
720-262-7002
주소
1715 38TH ST, BOULDER
Compare EWTX vs VRTX, REGN, ARGX, MRNA, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EWTX
Edgewise Therapeutics Inc
|
44.72 | 4.70B | 0 | -176.01M | -148.97M | -1.661 |
VRTX
Vertex Pharmaceuticals Inc
|
547.59 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
828.50 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,011.11 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.89 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
211.58 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
엣지와이즈 Stock (EWTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-25 | 개시 | Goldman | Neutral |
| 2025-07-30 | 개시 | Raymond James | Strong Buy |
| 2025-06-30 | 개시 | H.C. Wainwright | Buy |
| 2025-04-30 | 개시 | Guggenheim | Buy |
| 2025-04-02 | 다운그레이드 | Scotiabank | Sector Outperform → Sector Perform |
| 2025-03-07 | 개시 | Scotiabank | Sector Outperform |
| 2025-01-22 | 개시 | Stifel | Hold |
| 2024-11-22 | 개시 | Evercore ISI | Outperform |
| 2024-03-07 | 개시 | Piper Sandler | Overweight |
| 2023-05-01 | 개시 | Truist | Buy |
| 2022-08-25 | 다운그레이드 | Goldman | Neutral → Sell |
| 2022-04-13 | 개시 | RBC Capital Mkts | Outperform |
| 2022-01-28 | 개시 | Goldman | Neutral |
모두보기
엣지와이즈 주식(EWTX)의 최신 뉴스
Edgewise Therapeutics Is Maintained at Overweight by JP Morgan - Moomoo
EWTX Maintains Overweight Rating -- Price Target Raised to $60 - GuruFocus
JPMorgan Chase & Co. Forecasts Strong Price Appreciation for Edgewise Therapeutics (NASDAQ:EWTX) Stock - MarketBeat
Edgewise Therapeutics (EWTX) Is Up 6.6% After Wider Q2 Losses Highlight Rising SpendHas The Bull Case Changed? - simplywall.st
CYTK Stock Jumped To Over 2-Year Highs On HCM Trial Outcome – So, Why Are Analysts Bullish On Edgewise Therapeutics? - Stocktwits
Edgewise (EWTX) Results and Estimates: The Available Earnings Metric Delivers a Miss in the Available Record; Price Reaction: The Stock Ends Up 0.16% in Latest TradingConsensus Miss Rate - vinanet.vn
Edgewise Therapeutics: Servier Deal Creates A Self-Funded Cardiovascular Platform (EWTX) - Seeking Alpha
Edgewise Therapeutics (EWTX) corrects CFO option grant price - Stock Titan
Edgewise Therapeutics (EWTX) corrects CMO’s 65K option grant price - Stock Titan
Edgewise Therapeutics (EWTX) sets GC option price at $43.56 - Stock Titan
Edgewise Therapeutics (EWTX) gives CSO 65K options at $43.56 - Stock Titan
Edgewise (NASDAQ: EWTX) CBO gets 100K options vesting from 2026 - Stock Titan
69,441 Shares in Edgewise Therapeutics, Inc. $EWTX Bought by Persistent Asset Partners Ltd - MarketBeat
44,466 Shares in Edgewise Therapeutics, Inc. $EWTX Bought by GSA Capital Partners LLP - MarketBeat
Edgewise Therapeutics (EWTX) Reports Wider Losses On A Valuation That Still Looks Rich - Sahm
Edgewise Therapeutics (EWTX) Gains 2.29% to $44.17, Maintains Upside MomentumStock Surge Alerts - vinanet.vn
Edgewise Therapeutics CEO Kevin Koch sells $785,042 in stock By Investing.com - Investing.com South Africa
Edgewise Therapeutics CSO Alan Russell sells $258k in stock - Investing.com
Edgewise Therapeutics CEO Kevin Koch sells $785,042 in stock - Investing.com
Edgewise Therapeutics CSO Alan Russell sells $258k in stock By Investing.com - Investing.com South Africa
Edgewise Therapeutics CMO Joanne Donovan sells $412,703 in stock - Investing.com
Edgewise Therapeutics general counsel Moore sells $219,822 in shares - Investing.com
Edgewise Therapeutics CBO sells $223k in shares for tax obligations - Investing.com
Edgewise Therapeutics general counsel Moore sells $219,822 in shares By Investing.com - Investing.com Australia
Edgewise Therapeutics CMO Joanne Donovan sells $412,703 in stock By Investing.com - Investing.com Canada
Joanne Donovan Sells 2,919 Shares of Edgewise Therapeutics (NASDAQ:EWTX) Stock - MarketBeat
Edgewise Therapeutics (NASDAQ:EWTX) General Counsel Sells $219,801.12 in Stock - MarketBeat
Insider Selling: Edgewise Therapeutics (NASDAQ:EWTX) Insider Sells 5,901 Shares - MarketBeat
Edgewise Therapeutics President, CEO Sold Shares Worth Over $785K - TradingView
Edgewise Therapeutics (EWTX) GC nets RSU vesting, tax sales and new grants - Stock Titan
Edgewise Therapeutics (EWTX) grants CFO 24,375 RSUs and 48,750-share option - Stock Titan
Edgewise Therapeutics (EWTX) CSO gets 97,500-share equity awards, sells shares for taxes - Stock Titan
Edgewise Therapeutics (EWTX) CEO logs RSU vesting, sell-to-cover sales and 200,000 new options - Stock Titan
Edgewise Therapeutics (EWTX) grants 50,000 RSUs and 100,000 options to CBO - Stock Titan
RA Capital’s 7.8% Edgewise Therapeutics (EWTX) stake totals 8.39M shares - Stock Titan
Paradigm BioCapital reports 9.5% stake in Edgewise Therapeutics (EWTX) common stock - Stock Titan
Edgewise Therapeutics (EWTX): Baker Bros. discloses 3.4% ownership in Schedule 13G/A - Stock Titan
Bank of America Corp DE Decreases Position in Edgewise Therapeutics, Inc. $EWTX - MarketBeat
Edgewise Therapeutics, Inc. SEC Filing (Aug 13, 2026) - Stock Titan
Edgewise Therapeutics Inc (EWTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
FMR LLC Expands Edgewise Therapeutics Inc (EWTX) Stake With 4.47 Million Share Purchase - GuruFocus
Edgewise Therapeutics, Inc. $EWTX Shares Acquired by California State Teachers Retirement System - MarketBeat
Price-Driven Insight from (EWTX) for Rule-Based Strategy - Stock Traders Daily
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Edgewise Therapeutics Inc (EWTX) Stock News Today - TradingKey
Evercore Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Maintains Target Price $55 - Moomoo
FY2030 EPS Estimate for Edgewise Therapeutics Cut by Analyst - MarketBeat
Edgewise Therapeutics (NASDAQ:EWTX) Posts Earnings Results, Misses Estimates By $0.06 EPS - MarketBeat
Edgewise Therapeutics, Inc. Stock 12‑Month Price Target Raised to $50.46, Implies 12% Upside - TradingView
Edgewise ups R&D spending as pharma firm focuses on cardiovascular pipeline - BizWest
H.C. Wainwright Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Maintains Target Price $45 - Moomoo
엣지와이즈 (EWTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
엣지와이즈 주식 (EWTX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Donovan Joanne M. | CMO |
Aug 12 '26 |
Sale |
43.85 |
6,522 |
286,000 |
11,544 |
| Donovan Joanne M. | CMO |
Aug 13 '26 |
Sale |
43.41 |
2,919 |
126,704 |
8,625 |
| Russell Alan J | Chief Scientific Officer |
Aug 12 '26 |
Option Exercise |
0.00 |
12,812 |
0 |
37,367 |
| Russell Alan J | Chief Scientific Officer |
Aug 12 '26 |
Sale |
43.73 |
5,901 |
258,042 |
31,466 |
| MOORE JOHN R | General Counsel |
Aug 12 '26 |
Option Exercise |
0.00 |
12,499 |
0 |
22,713 |
| MOORE JOHN R | General Counsel |
Aug 12 '26 |
Sale |
43.82 |
5,016 |
219,823 |
17,697 |
| Derakhshan Behrad | Chief Business Officer |
Aug 12 '26 |
Option Exercise |
0.00 |
13,281 |
0 |
36,926 |
| Derakhshan Behrad | Chief Business Officer |
Aug 12 '26 |
Sale |
43.81 |
5,100 |
223,424 |
31,826 |
| KOCH KEVIN | President and CEO |
Aug 12 '26 |
Option Exercise |
0.00 |
39,844 |
0 |
70,459 |
| KOCH KEVIN | President and CEO |
Aug 12 '26 |
Sale |
43.68 |
17,971 |
785,042 |
52,488 |
0.00%
3.22%
자본화:
|
볼륨(24시간):